Genmab launches “AI Everywhere”

Genmab(opens in a new window), a leading global biotechnology company, is pioneering next-generation antibody therapies to treat cancer and other serious diseases. Their mission is ambitious: to revolutionize patient care with transformative “knock-your-socks-off” (KYSO^®) antibody treatments. 

“Genmab’s ambition is to integrate AI into everything we do,” said Tahi Ahmadi, Executive Vice President and Chief Medical Officer, Head of Experimental Medicines. “We anticipated AI to contribute significantly to the quality of our science, decision making, and efficiency in bringing medicines to patients.”

As a company that has recently tripled in size, Genmab wanted to use AI to address operational challenges—and develop new ways of working with vast amounts of complex scientific data. 

Just one month after ChatGPT Enterprise launched, Genmab rolled it out to 1,000 employees. Now, less than a year later, they’ve launched “AI Everywhere” to give ChatGPT access to almost everyone at the company—more than 2,000 licenses.

To provide a starting point for employees, Genmab had a simple but effective idea: they encouraged employees to give ChatGPT Enterprise their job description and ask, “What can you do to help me?”

By scaling the adoption of tools like ChatGPT, Genmab invests in every employee’s continuous learning journey. 

In a recent survey, employees reported that ChatGPT Enterprise saves them an average of 3.5 hours per week, and many could not imagine performing aspects of their jobs without these newfound capabilities. 

Genmab now has more than 100 custom GPTs that help with everything from drafting documents, summarizing scientific literature to simple and advanced analytics of data. 

The recent release of GPT-4o’s vision enhancements has enabled Genmab to tackle tasks that were impossible even just three months ago. Specifically, the model now interprets complex documents containing images, text, and numbers in a human-like manner. This advancement offers a new, more efficient approach to verifying factual references in medical affairs publications, reducing the significant time and costs previously required for this process.

Genmab recently launched an innovative project to transform the creation of clinical trial documents, including clinical study reports (CSRs), patient safety narratives, and investigational new drug (IND) applications, using GPT-4o. By integrating GPT-4o directly with clinical data and clinical feedback, they’ve taught the model to continuously improve its own drafts, behaving more like a person solving complex problems. 

Genmab has rapidly developed AI Translator GPT, a cutting-edge tool that translates complex scientific documents with human-like accuracy using OpenAI models. The model mimics a human translation team, assuming roles such as translator, editor, and even a specialized agent for complex biological content. It also includes a unique reverse translation process (to see what is lost and prompt a new translation editing cycle) and when needed, a staging language approach for translating English to Chinese through Japanese, significantly reducing translation time from weeks to mere hours or minutes and saving significant costs.

By the numbers:

• 100+ custom GPTs built and rolled out across the company

• Each user has 120 ChatGPT Enterprise conversations per week on average

• 3.5 hours average time savings per week

Genmab considers data privacy and security paramount. So, to facilitate the deployment and full utility of ChatGPT for the enterprise, the company conducted a thorough evaluation of OpenAI for security and privacy compliance by running a detailed assessment that included:

• Reviewing data handling practices

• Encryption standards, and 

• Compliance with international data protection regulations such as GDPR.

This evaluation involved a series of audits and consultations with internal and external experts to ensure that OpenAI’s AI solutions met Genmab’s stringent requirements for protecting sensitive data and maintaining confidentiality. 

Working directly with OpenAI means Genmab gets to work hands-on with AI experts that share a mission to advance and accelerate scientific progress.

“We considered working with a cloud provider, but value the direct relationship with OpenAI. By working with the OpenAI team, we have access to the applied, research and deployment organizations that can partner with us on new initiatives and push the capabilities of our solutions,” said Hamadeh. 

AI is poised to become even more integral to the biopharmaceutical industry where advancements are expected to include significantly more powerful and efficient models capable of unprecedented levels of reasoning and understanding,

“Our vision goes beyond just streamlining processes; we're aiming to fundamentally transform how we discover, develop, and deliver treatments to patients,” said Scott Ogden, Head of Genmab’s AI Lab.